Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center

Clin Infect Dis. 2017 Nov 29;65(12):2105-2111. doi: 10.1093/cid/cix725.

Abstract

Background: The risk of infection with Mycobacterium tuberculosis among healthcare workers (HCWs) is estimated to be higher than the general population. However, HCW acceptance and compliance with available latent tuberculosis infection (LTBI) treatment regimens has been problematic. Recently, regimens have become available that might improve HCW acceptance and compliance with LTBI treatment.

Methods: A retrospective single-center review of Employee Health and Wellness Services records of all HCWs diagnosed with LTBI was conducted. HCWs diagnosed with LTBI were offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) for 12 weeks, or no treatment. Acceptance, completion rates, and side effects were reported for each regimen. Comparisons of regimens were assessed using Fisher exact test.

Results: Between 2005 and 2014, 363 of 927 (39%) HCWs diagnosed with LTBI accepted treatment. Of 363, 202 chose INH, 106 RIF, and 55 RPT/INH. Completion rates for each regimen were 58%, 80%, and 87%, respectively. HCWs were significantly more likely to have completed treatment with RIF (P < .0001) or RPT/INH (P < .0001) than INH. Rates of discontinuation owing to side effects were 35% for INH, 21% for RIF, and 10% for RPT/INH. Discontinuation of therapy due to side effects was significantly more frequent in the INH than the RPT/INH group (P = .0042).

Conclusions: Completion of RIF and RPT/INH for LTBI in an HCW population is more likely than INH. Rates of discontinuation due to side effects were lower among those taking RPT/INH. Shorter LTBI treatment regimens should be more widely considered for HCWs in the United States.

Keywords: healthcare workers; isoniazid; latent tuberculosis infection; rifampin; rifapentine.

MeSH terms

  • Adult
  • Antitubercular Agents / adverse effects
  • Antitubercular Agents / therapeutic use*
  • Disease Management*
  • Drug Therapy, Combination / adverse effects
  • Female
  • Health Personnel / organization & administration
  • Health Personnel / statistics & numerical data*
  • Humans
  • Isoniazid / adverse effects
  • Isoniazid / therapeutic use
  • Latent Tuberculosis / diagnosis
  • Latent Tuberculosis / drug therapy*
  • Latent Tuberculosis / epidemiology
  • Male
  • Middle Aged
  • Retrospective Studies
  • Rifampin / adverse effects
  • Rifampin / analogs & derivatives
  • Rifampin / therapeutic use

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin
  • rifapentine